Abstract
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
Keywords: Clinical, colorectal cancer, DPYD, RAS, targeted therapy, TRAIL.
Current Clinical Pharmacology
Title:Novel and Emerging Targeted Therapies of Colorectal Cancer
Volume: 10 Issue: 4
Author(s): Niklas Finnberg, Prashanth Gokare and Wafik S. El-Deiry
Affiliation:
Keywords: Clinical, colorectal cancer, DPYD, RAS, targeted therapy, TRAIL.
Abstract: The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
Export Options
About this article
Cite this article as:
Finnberg Niklas, Gokare Prashanth and El-Deiry S. Wafik, Novel and Emerging Targeted Therapies of Colorectal Cancer, Current Clinical Pharmacology 2015; 10 (4) . https://dx.doi.org/10.2174/1574884710666151020095911
DOI https://dx.doi.org/10.2174/1574884710666151020095911 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Comparative Evaluation of Colon Cancer Specific Antigen-2 Test and Chromocolonoscopy for Early Detection of Egyptian Patients with Colorectal Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Current Pharmaceutical Design Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
Current Medicinal Chemistry Traditional Uses, Therapeutic Effects and Recent Advances of Curcumin: A Mini-Review
Mini-Reviews in Medicinal Chemistry Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Editorial [Hot Topic: Biomarkers of Chemotherapeutics Efficacy and Toxicity in Colorectal Cancer (Guest Editor: Amalia Azzariti)]
Current Drug Metabolism Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets